Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Evidence suggests a role for small intestinal bacterial overgrowth (SIBO) in IBS. Recently, the question has arisen whether the lactulose breath test (LBT) is abnormal in IBS subjects due to overlapping GERD and proton-pump inhibitor (PPI) usage.
The aim of this study was to compare the prevalence of an abnormal LBT in IBS patients either receiving or not receiving PPI therapy.
Consecutive Rome I positive IBS patients referred for LBT completed a questionnaire regarding their symptoms and medication use. All subjects then underwent an LBT. The prevalence of abnormal breath test results and hydrogen production were compared based on PPI usage.
Of a total of 555 (429 female) subjects, 106 (19.1%) subjects reported current PPI use. Among those on PPI, 46.2% had a positive LBT. This was not different from the 56.3% positive LBT in non-PPI subjects (OR = 0.67, CI = 0.436–1.017, P = 0.06). No differences in hydrogen parameter were seen with PPI. The average amplitude of rise (first peak) in PPI users was 28.0 ± 35.3 ppm from baseline; in non-PPI users it was 27.5 ± 29.1 ppm (P = 0.89). The average rise in the second peak in PPI users was 48.5 ± 43.8 ppm from baseline; in non-PPI users, it was 49.3 ± 37.6 ppm (P = 0.87). The time to first peak in PPI users was 56.4 ± 23.0 min; in non-PPI users, it was 58.2 ± 26.1 min (P = 0.58). However, among subjects receiving PPI only 7.5% had methane detection on LBT, which is significantly different from the 15.4% of subjects not taking PPI.
PPI therapy does not effect hydrogen production on lactulose breath tests in IBS patients. However, there may be an effect on methane.
- Bommelaer, G, Poynard, T, Le Pen, C, Gaudin, AF, Maurel, F, Priol, G (2004) Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol 28: pp. 554-561 CrossRef
- Wilson, S, Roberts, L, Roalfe, A, Bridge, P, Singh, S (2004) Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 54: pp. 495-502
- Gwee, KA, Wee, S, Wong, ML, Png, DJ (2004) The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol 99: pp. 924-931 CrossRef
- El-Serag, HB (2003) Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord 3: pp. S3-S11
- Hungin, AP, Whorwell, PJ, Tack, J, Mearin, F (2003) The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Ailment Pharmacol Ther 17: pp. 643-650 CrossRef
- Agreus, L, Svardsudd, K, Nyren, O, Tibblin, G (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109: pp. 671-680 CrossRef
- Drossman DA, Richter JE, Talley NJ, et al. (eds) Functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus. Boston: Little Brown, 1994.
- Pimentel, M, Chow, EJ, Lin, HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95: pp. 3503-3506 CrossRef
- Pimentel, M, Chow, EJ, Lin, HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: pp. 412-419
- Lupascu, A, Gabrielli, M, Lauritano, EC (2005) Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 22: pp. 1157-1160 CrossRef
- Grover, M, Kanazawa, M, Palsson, OS (2008) Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, psychological distress. Neurogastroenterol Motil 20: pp. 998-1008 CrossRef
- McCallum, R, Schultz, C, Sostarich, S (2005) Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT). Gastroenterol 128: pp. A460
- Pimentel, M, Park, S, Mirocha, J (2006) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: pp. 557-563
- Al, Shahara, Aoun, E, Abdul-Baki, H, Mounzer, R, Sidani, S, ElHajj, I (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: pp. 326-333 CrossRef
- Lembo A, Zakko S, Ferreira N, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134:A-545.
- Nastaskin, I, Mehdikhani, E, Conklin, J (2006) Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 51: pp. 2113-2120 CrossRef
- Posserud, I, Stotzer, PO, Bjornsson, ES, Abrahamsson, H, Simren, M (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56: pp. 802-808 CrossRef
- Spiegel, BMR, Chey, WD, Chang, L (2006) Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?. Am J Gastroenterol 103: pp. 2972-2976 CrossRef
- Khoshini, R, Dai, SC, Lezcano, S, Pimentel, M (2008) A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 53: pp. 1443-1454 CrossRef
- Riedl, A, Schmidtmann, M, Stengel, A, Goebel, M, Wisser, AS, Klapp, BF, Monnikes, H (2008) Somatic comorbidities of IBS: a systematic analysis. J Psychosom Res 64: pp. 573-582 CrossRef
- Williams, C, McColl, KEL (2006) Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 23: pp. 3-10 CrossRef
- Theisen, J, Nehra, D, Citron, D (2000) Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 4: pp. 50-54 CrossRef
- Lewis, SJ, Franco, S, Young, G, O’Keefe, SJD (1996) Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharm Ther 10: pp. 557-561 CrossRef
- Pereira, SP, Gainsborough, N, Dowling, RH (1998) Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther 12: pp. 99-104 CrossRef
- Fried, M, Siegrist, H, Frei, R (1994) Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 35: pp. 23-26 CrossRef
- Pimentel, M, Mayer, AG, Park, S (2003) Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 48: pp. 86-92 CrossRef
- Pimentel, M, Lin, HC, Enayati, P (2006) Methane, a gas produced by enteric bacteria, slows intestinal transit and augments ileal contractile activity. Am J Physiol Gastrointest Liver Physiol 290: pp. G1089-G1095 CrossRef
- Locke, GR, Zinsmeister, AR, Fett, SL (2005) Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 14: pp. 29-34 CrossRef
- Thorens, J, Froehlich, F, Schwizer, W (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 39: pp. 54-59 CrossRef
- Rubinstein, E, Mark, Z, Haspel, J (1985) Antibacterial activity of the pancreatic fluid. Gastroenterol 88: pp. 927-932
- Fass, R, Shapiro, M, Dekel, R, Sewell, J (2005) Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease––where next?. Aliment Pharmacol Ther 22: pp. 79-94 CrossRef
- Neal, KR, Scott, HM, Slack, RCB, Logan, RFA (1996) Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study. BMJ 312: pp. 414-415
- Dial, S, Alrasadi, K, Manoukian, C, Huang, A, Menzies, D (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 6: pp. 33-38 CrossRef
- Cunningham, R, Dale, B, Undy, B, Gaunt, N (2003) Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 54: pp. 243-245 CrossRef
- Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS
Digestive Diseases and Sciences
Volume 55, Issue 8 , pp 2302-2308
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Proton pump inhibitor
- Lactulose breath test
- Industry Sectors